Eledon Pharmaceuticals (ELDN) Liabilities and Shareholders Equity (2013 - 2026)

Eledon Pharmaceuticals' Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $146.7 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 9.08% year-over-year to $146.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $590.4 million (up 2.91% YoY) and the FY2025 annual result came in at $169.0 million, down 4.73% from the prior year.
• Liabilities and Shareholders Equity was $146.7 million for Q1 2026 at Eledon Pharmaceuticals, down from $169.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $177.4 million in Q4 2024 and bottomed at $80.8 million in Q1 2024.
• A 5-year average of $128.1 million and a median of $129.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity tumbled 49.0% — and 2025, when it soared 99.59%.
• Eledon Pharmaceuticals' Liabilities and Shareholders Equity stood at $92.8 million in 2022, then retreated by 4.02% to $89.1 million in 2023, then jumped by 99.18% to $177.4 million in 2024, then fell by 4.73% to $169.0 million in 2025, then retreated by 13.22% to $146.7 million in 2026.
• Business Quant data shows ELDN's Liabilities and Shareholders Equity at $146.7 million in Q1 2026, $169.0 million in Q4 2025, and $129.9 million in Q3 2025.